Ann: Phase One and Two Clinical Program Update, page-13

TT,

You are still focusing on BL instead of the Cannabinoid strains we have.

Human (adolescent children - a first with any CBD ) trials are due to start any day now and we will see what the market thinks of that.

We have gained the support of Andrew Chapman from Merchant Funds Management whom have guaranteed us an extra $3.56, between 5.5c to 6c

No one can question his pedigree with significant wins in Polynovo (40 x) RAC (7x) and BD1 (7x) and still holding around $45m of each of the later two.

But you keep commenting on BL and to date I think you have been 100% wrong when it comes to this stock.

Cheers